📰 Scott Akamine News
Scott Akamine News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Scott Akamine. Real-time updates on events, politics, business and more.
February 27, 2024
Avidity Partners Management LP raised its holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) by 28.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 643,000 shares of the biotechnology company’s stock after purchasing an additional 141,800 shares during the quarter. […]
February 20, 2024
Cerevel Therapeutics (NASDAQ:CERE – Free Report) had its price objective upped by Mizuho from $25.00 to $45.00 in a report issued on Friday morning, Benzinga reports. Mizuho currently has a neutral rating on the biotechnology company’s stock. A number of other equities analysts also recently commented on the company. Jefferies Financial Group reiterated a hold […]
February 20, 2024
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) shares saw an uptick in trading volume on Tuesday . 1,343,879 shares were traded during trading, a decline of 20% from the previous session’s volume of 1,682,243 shares.The stock last traded at $41.20 and had previously closed at $42.57. Analyst Upgrades and Downgrades A number of […]
February 20, 2024
Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) saw strong trading volume on Tuesday . 1,343,879 shares were traded during trading, a decline of 20% from the previous session’s volume of 1,682,243 shares.The stock last traded at $41.20 and had previously closed at $42.57. Wall Street Analysts Forecast Growth A number of […]
February 20, 2024
Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) saw strong trading volume on Tuesday . 1,343,879 shares were traded during trading, a decline of 20% from the previous session’s volume of 1,682,243 shares.The stock last traded at $41.20 and had previously closed at $42.57. Wall Street Analysts Forecast Growth A number of […]
December 11, 2023
HC Wainwright lowered shares of Cerevel Therapeutics (NASDAQ:CERE – Free Report) from a buy rating to a neutral rating in a report released on Thursday, MarketBeat reports. They currently have $45.00 price target on the biotechnology company’s stock, up from their previous price target of $41.00. A number of other research firms have also recently […]
December 11, 2023
Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) saw unusually-high trading volume on Monday . Approximately 1,343,201 shares traded hands during mid-day trading, an increase of 45% from the previous session’s volume of 927,215 shares.The stock last traded at $41.07 and had previously closed at $41.22. Wall Street Analysts Forecast Growth CERE […]
December 10, 2023
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) insider Scott Akamine sold 10,000 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $41.37, for a total value of $413,700.00. Following the completion of the sale, the insider now owns 513 shares of […]
December 10, 2023
Jefferies Financial Group Inc. cut its stake in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) by 50.0% during the 2nd quarter, Holdings Channel reports. The fund owned 25,000 shares of the biotechnology company’s stock after selling 25,020 shares during the period. Jefferies Financial Group Inc.’s holdings in Cerevel Therapeutics were worth $795,000 […]